GLP-1 30MG
GLP-1 30MG Vial is a high-purity glucagon-like peptide-1 analog supplied in a convenient research-grade vial format for controlled laboratory use. Developed for investigators exploring incretin biology, metabolic regulation, and insulinotropic signaling, this peptide offers consistent performance across in vitro and preclinical study designs. Each 30 mg presentation supports flexible dosing regimens, enabling detailed evaluation of GLP-1–mediated pathways, including insulin secretion, appetite modulation, and energy balance. GLP-1 30MG Vial is intended strictly for research applications and is not for human or veterinary use.
$311.25
đźšš Free shipping on all orders (US Only )
🔄 All sales are final
FDA Disclaimer:Â The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. All products are for laboratory developmental research USE ONLY. Products are not for human consumption.
Overview
– Supports targeted investigation of GLP-1 receptor–mediated signaling in metabolic research models
– Enables controlled evaluation of insulin secretion, appetite regulation, and energy balance mechanisms
– Supplied as a 30 mg vial to accommodate a wide range of experimental dosing strategies
– Suitable for in vitro and preclinical applications within controlled research environments
– Manufactured as a research-use-only material, not intended for diagnostic or therapeutic use
Structure
Glucagon-like peptide-1 (GLP-1) is a 30–31 amino acid incretin hormone derived from proglucagon, typically represented by the active fragment GLP-1(7–36) amide. The native peptide adopts an alpha-helical conformation in aqueous and membrane-mimetic environments, a structural feature that is critical for high-affinity engagement of the GLP-1 receptor, a class B G protein–coupled receptor. Conserved N-terminal residues are essential for receptor activation, while central and C-terminal regions stabilize receptor binding and contribute to overall conformational integrity during signal transduction.
Research
GLP-1 30MG Vial is intended for mechanistic and translational studies focused on the glucagon-like peptide-1 receptor (GLP-1R), a key regulator of glucose homeostasis and energy balance. In experimental systems, GLP-1 analogs are widely used to probe cAMP-dependent signaling, insulinotropic responses in pancreatic beta cells, modulation of glucagon secretion, and effects on gastric emptying and appetite control. By selectively activating GLP-1R, researchers can dissect downstream pathways involving G protein coupling, second messenger dynamics, and cross-talk with other metabolic hormones in models of diabetes, obesity, and cardiometabolic disease.
Referenced Citations
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metabolism, 27*(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Muller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). *Molecular Metabolism, 30*, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Nauck, M. A., & Meier, J. J. (2019). Incretin hormones: Their role in health and disease. *Diabetes, Obesity and Metabolism, 21*(S1), 5–21. https://doi.org/10.1111/dom.13605
Holst, J. J. (2022). The physiology of glucagon-like peptide 1. *Physiological Reviews, 102*(4), 1567–1622. https://doi.org/10.1152/physrev.00034.2020